Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...

New Yorkers: there is an active shooter investigation taking place in Midtown right now. Please take proper safety ...

A police officer and one other person were shot at an office skyscraper in midtown Manhattan Monday evening, according to law ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

AI insights suggest a bullish near-term outlook for BMY. The risk-reward ratio heavily favors a long position, sitting pretty ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...